Instem plc
("Instem" or the "Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, following the exercise of share options by certain members of the senior management team, 38,667 new ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.
Application has been made to the London Stock Exchange for the admission of the 38,667 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 26 April 2021.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 21,780,699 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 21,780,699.
The figure of 21,780,699 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
| Instem plc | via Walbrook Financial PR |
| Phil Reason, CEO | |
| Nigel Goldsmith, CFO | |
| | |
| N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| Peter Steel / Alex Bond (Corporate Finance) | |
| | |
| Walbrook Financial PR | +44 (0) 20 7933 8000 |
| Nick Rome | |
| Tom Cooper Nicholas Johnson | |
| | |
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by over 600 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
